Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals International, plc stock.
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) generates frequent news through its work as a biopharmaceutical company focused on cardiovascular indications and diseases with unmet need. Company press releases and Form 8‑K filings highlight developments around its IL‑1 pathway franchise, including the commercial performance of ARCALYST (rilonacept) and the clinical progress of investigational monoclonal antibodies KPL‑387 and KPL‑1161.
News items commonly cover quarterly and annual financial results, where Kiniksa reports ARCALYST net product revenue, trends in prescriber adoption, and changes in guidance for expected ARCALYST net product revenue. These updates often include commentary on the uptake of IL‑1α and IL‑1β inhibition in recurrent pericarditis, the proportion of multiple‑recurrence patients on ARCALYST therapy, and the average duration of treatment.
Investors following KNSA news also see regular clinical and regulatory milestones. Kiniksa has announced the initiation and design of a Phase 2/3 clinical trial of KPL‑387 in recurrent pericarditis, Phase 1 data supporting a monthly dosing profile, and the U.S. FDA’s Orphan Drug Designation for KPL‑387 for the treatment of pericarditis. Additional updates describe preclinical or IND‑enabling activities for KPL‑1161, which has a target profile of quarterly subcutaneous dosing.
Corporate and investor‑relations announcements form another key part of the KNSA news flow. The company frequently issues notices about upcoming and completed presentations at healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference, Jefferies Global Healthcare Conference, and other biopharma‑focused events. These communications typically reference webcasts and replays available through Kiniksa’s investor channels.
By monitoring this news stream, readers can track how Kiniksa manages ARCALYST commercialization, advances its IL‑1R1‑targeted pipeline, and updates its financial outlook. The KNSA news page on Stock Titan aggregates these releases so investors and observers can review earnings announcements, trial updates, regulatory designations, and conference participation in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Kiniksa Pharmaceuticals reported Q4 2022 net product revenue of ARCALYST at $39.9 million and full-year revenue of $122.5 million. For 2023, net product revenue is expected between $190 million and $205 million, indicating over 60% growth from 2022. The average therapy duration was approximately 18 months, with a strong payer approval rate exceeding 90%. Kiniksa maintains cash reserves to support operations through at least 2025. Financially, total revenue for 2022 reached $220.2 million with a net income of $183.4 million, boosted by a significant tax benefit.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will host a conference call on February 28, 2023, at 8:30 a.m. ET, to discuss its fourth quarter and full-year 2022 financial results and recent portfolio execution.
The call will be accessible via a live webcast on Kiniksa's website. Telephone participants must register to receive dial-in details. A replay will be available approximately 48 hours post-event. Kiniksa focuses on developing therapeutic medicines for critical unmet medical needs, with assets like ARCALYST and KPL-404 targeting cardiovascular and autoimmune conditions.
Kiniksa Pharmaceuticals (KNSA) reported net product revenue of $39.9 million for Q4 2022 and $122.5 million for full-year 2022. The company's cash reserves of $190.4 million are projected to support operations through 2025. Kiniksa has enrolled 2 of 3 cohorts in the Phase 2 trial of KPL-404 for rheumatoid arthritis, with results expected in 1H 2024. The company aims to grow its cardiovascular franchise through ARCALYST sales and collaborative agreements for mavrilimumab, indicating a focus on strategic portfolio optimization.